Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07439250) titled 'A Study of Olomorasib (LY3537982) in Healthy Participants' on Feb. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).

Primary Sponsor: Eli Lilly and Company

Condition: Healthy

Intervention: Drug: Olomorasib

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: March 2026

Target Sample Size: 15

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07439250

Published by HT Digital Content Services with permission from Health...